Thromboinflammation – Page 4 – Communicable Diseases Research

Incidence of Deep Venous Thrombosis in Patients With COVID-19 and Pulmonary Embolism: Compression Ultrasound COVID Study

Observational Study

Published on 2021-07-012022-10-05
Journal: Journal of Ultrasound in Medicine [Category] SARS, 임상,

Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19

Article

Published on 2021-06-302022-10-29
Journal: International Journal of Molecular Sciences [Category] COVID-19, MERS, SARS,

[키워드] ACE2 acute respiratory syndrome binding energy BTK BTK inhibitor BTK inhibitors carried caused clinical trial complexes computational studies conducted coronavirus COVID-19 COVID-19 patient disease docking drug Dyspnea Health Host hypercoagulability hypoxia Ibrutinib IMPROVE inhibitor inhibitors of SARS-CoV-2 inositol 1,3,4,5-tetrakisphosphate MD simulations mechanism mechanism of action molecular nonstructural protein Oxygenation Pathogenesis Potential protein-ligand binding free energy recent reduce Replication reported Result SARS-CoV-2 screened Screening selected spebrutinib target Thromboinflammation TMPRSS2 treat tyrosine viral entry Virtual screening zanubrutinib
[DOI] 10.3390/ijms22137071 PMC 바로가기 [Article Type] Article

The Emerging Role of Neutrophils in the Pathogenesis of Thrombosis in COVID-19

Review

Published on 2021-05-202022-10-29
Journal: International Journal of Molecular Sciences [Category] COVID-19, SARS,

Pathophysiological Association of Endothelial Dysfunction with Fatal Outcome in COVID-19

Review

Published on 2021-05-122022-10-29
Journal: International Journal of Molecular Sciences [Category] COVID-19, SARS,

[키워드] accumulating acute respiratory distress angiotensin-converting enzyme 2 Betacoronavirus Bioavailability caused Coagulation Complication contribute contributing to coronavirus disease COVID-19 dysfunction Endothelial cell Endothelial dysfunction endothelial function Endothelium Evidence Healthcare systems hypoxic respiratory failure indicated infect Inflammation instance morbidity and mortality Mortality nitric oxide outbreak outcome Pathogenesis pathway Patient patients with COVID-19 recent reduced risk SARS-CoV-2 SARS-COV-2 infection severe COVID-19 severe disease shown syndrome Thromboembolic event Thromboembolism Thromboinflammation thrombotic complication Viral pneumonia virus infection
[DOI] 10.3390/ijms22105131 PMC 바로가기 [Article Type] Review

Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial

Randomized Controlled Trial

Published on 2021-05-012022-10-04
Journal: International journal of antimicrobial agents [Category] 임상,

[키워드] 95% CI acute respiratory distress syndrome addition age Analysis ARDS assessment association Care clinical trial COVID-19 COVID-19 patients Cytokine release syndrome D-dimer Day distress Efficacy enrolled faster clinical recovery ferritin hyperinflammation ICU ICU patient inflammatory biomarkers intensive care unit interleukin-6 IQR Kaplan-Meier lactate dehydrogenase life-threatening LOS lymphocyte Mortality Multivariable regression analysis on mechanical ventilation Open-label Organ failure outcome PaO Patient plasma positive predictor provided randomised randomised controlled reduction in RT-qPCR secondary Sepsis serum lactate SOFA score Standard standard care standard treatment stratified Therapeutic plasma exchange therapy Thromboinflammation TPE Treatment
[DOI] 10.1016/j.ijantimicag.2021.106334 PMC 바로가기 [Article Type] Randomized Controlled Trial

Thrombotic Events in COVID-19 Are Associated With a Lower Use of Prophylactic Anticoagulation Before Hospitalization and Followed by Decreases in Platelet Reactivity

Medicine

Published on 2021-04-222022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

[키워드] 95% CI 95% confidence interval adjusted odds ratio ADP age all-cause mortality AOR association Asthma baseline blood sample clinical Clinical outcome control patient COVID-19 COVID-19 negative COVID-19 positive patient decrease determine develop disease enrolled expression flow cytometry followed by highlight Hospitalized hospitalized COVID-19 patient hypercoagulability incidence increased the risk less Lower nine Non-survivors outcome P-selectin Patient Platelet Platelets positive prothrombotic state provided pulmonary thrombosis reactivity retrospective cohort study risk SARS-CoV-2 significant difference survivor therapy Thromboinflammation Thromboprophylaxis thrombosis thrombotic thrombotic event Thrombotic events was determined with COVID-19
[DOI] 10.3389/fmed.2021.650129 PMC 바로가기 [Article Type] Medicine

Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics

보완 시스템의 치료적 표적화: 희귀 질병에서 유행병까지

Article

Published on 2021-04-012022-09-12
Journal: Pharmacological reviews [Category] MERS, SARS, 진단,

[키워드] activate approved Atypical candidate chronic disease Clinical treatment clinical trials common disease complement contribute COVID-19 COVID-19 disease death Defense disease disease pathogenesis Diseases disorders dysfunction dysregulated Evidence example Hemostasis homeostasis Host include Inflammation innate immune system invading pathogens ischemia-reperfusion injury killing microbes modulation molecular pattern multifunctional Myocardial infarction neurologic organ Organ failure pandemic coronavirus paroxysmal nocturnal hemoglobinuria pathogen-associated molecular patterns patient group pharmacological strategy pharmacological treatment plasma PROTECT rare disease robust Sepsis severe coronavirus disease stroke syndrome systemic inflammatory targeting the antibody Therapies therapy Thromboinflammation tissue damage tissue regeneration tissue repair trauma treat treated Treatment
[DOI] 10.1124/pharmrev.120.000072 PMC 바로가기 [Article Type] Article

Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection

보완 과잉 활성화 및 소비는 SARS-CoV-2 감염의 병원 내 사망률을 예측합니다

Clinical Trial

Published on 2021-03-252022-08-13
Journal: Frontiers in Immunology [Category] SARS, 임상,

[키워드] 95% CI accompanied Activation advanced disease analyzed anaphylatoxin anaphylatoxin C3a C-reactive protein C3a/C3 caused characteristic classical pathways clinical complement Complement activation complement activation and consumption complement inhibitory drug complement inhibitory drugs complement profile complement system Consumption coronavirus coronavirus disease coronavirus disease (COVID-19) covariate COVID-19 COVID-19 related mortality COVID-19 severity Cox model decrease enzyme-immunoassays Evidence Factors ferritin hemolytic hemolytic titration hospital Hospital stay Hospitalized hospitalized COVID-19 patients implicated In-hospital in-hospital mortality Increased Inflammation interleukin interleukin-6 marker Mortality objective Ordinal Scale outcome Outpatient overactivation Pathogenesis patients died PCR-confirmed COVID-19 predictor Primary outcome prospective cohort study Result SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 virus secondary outcome severity severity of COVID-19 significantly Support the disease the WHO Thromboinflammation Treatment treatment of COVID-19 turbidimetry uncontrolled were measured WHO ordinal scale
[DOI] 10.3389/fimmu.2021.663187 PMC 바로가기 [Article Type] Clinical Trial

Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications

Review

Published on 2021-03-012022-10-31
Journal: Diabetology & Metabolic Syndrome [Category] COVID-19,

The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System

중환자 COVID-19 환자의 결과는 칼리크레인/키닌 시스템이 지배하는 혈소판 염증과 관련이 있습니다

Observational Study

Published on 2021-02-222022-09-11
Journal: Frontiers in Immunology [Category] MERS, 바이오마커, 임상, 진단,

[키워드] activated Activation Analysis Angiogenesis ARDS association biochemical parameter Biomarkers Blood C3a C4d cascade Clinical outcome Coagulation Coagulation system complement complement system components Contact COVID-19 COVID-19 patient Critically ill critically ill COVID-19 patients Critically ill patient critically ill patients D-dimer death debris demonstrated driving drug eliminating Evidence fibrinolysis system ICU Ill Illness severity Inflammation inhibitor innate immune system involved kallikrein/kinin system kidneys lung Lung injury microorganism molecular weight organ damage outcome Pathogenesis pathogenesis of COVID-19 Patient patients with COVID-19 prekallikrein Prognosis Prognostic marker Prospective Study recognizing reflected SC5b-9 severe COVID-19 Strong survival System TAT the patient Thromboinflammation thrombosis Treatment Uppsala University Vascular with COVID-19
[DOI] 10.3389/fimmu.2021.627579 PMC 바로가기 [Article Type] Observational Study